Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing

Inclusion Criteria: Subjects will be eligible if the following criteria are met: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \>18 years * Diagnosis of Type 1 or Type 2 diabetes * BCVA score using the ETDRS method of \>24 and \<78 in the study eye at the screening visit * 3 or more intravitreal injections of AntiVEGF over the 5 months prior to screening * Presence of diabetic macular edema defined as SD-OCT CST \>320 microns on spectral domain machine Exclusion Criteria: * Subjects who meet any of the following criteria will be excluded from this study: * Anti-VEGF treatment in the study eye within 3 weeks prior to screening * Intravitreal Ozurdex treatment in the study eye within 12 weeks prior to screening * Intravitreal steroid treatment in the study eye within 8 weeks prior to screening * PRP or focal laser in the study eye within 4 months prior to screening * Active iris neovascularization in the study eye * Any ocular condition in the study eye that, in the opinion of the investigator, is severe enough to compromise the study result. * History of cataract surgery in the study eye within 3 months prior to screening visit * Uncontrolled systemic disease * Current enrollment in an investigational drug study or participation in such a study within 30 days prior to the screening visit * Female patients who are pregnant, nursing or planning a pregnancy or who are of childbearing potential and not using a reliable means of contraception. * Any condition or reason (including inability to read ETDRS chart or language barrier) that precludes the patient's ability to comply with study requirements including completion of the study. * Known allergy, hypersensitivity or contraindication to the study medications, its components, fluorescein or povidone iodine.